

Brca2 Cas9-CKO Strategy


Designer: Design Date:

0.

Jinling Wang 2019-7-19

Project Overview






Conditional Knockout strategy



400-9660890

This model will use CRISPR/Cas9 technology to edit the *Brca2* gene. The schematic diagram is as follows:



江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.



The Brca2 gene has 14 transcripts. According to the structure of Brca2 gene, exon3-exon8 of Brca2-201 (ENSMUST00000044620.10) transcript is recommended as the knockout region. The region contains 590bp coding sequence. Knock out the region will result in disruption of protein function.

In this project we use CRISPR/Cas9 technology to modify *Brca2* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice.Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.

The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.



- According to the existing MGI data, Homozygous null mutants are embryonic lethal with abnormalities including growth retardation, neural tube defects, and mesoderm abnormalities; conditional mutations cause genetic instability and enhanced tumor formation; mutants with truncated BRCA2 protein survive, are small, infertile, show improper tissue differentiation and develop lymphomas and carcinomas.
- The Brca2 gene is located on the Chr5. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases. Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

Gene information (NCBI)



\$?

Brca2 breast cancer 2, early onset [Mus musculus (house mouse)]

Gene ID: 12190, updated on 9-Apr-2019

Summary

Official Symbol	Brca2 provided by MGI
Official Full Name	breast cancer 2, early onset provided by MGI
Primary source	MGI:MGI:109337
See related	Ensembl:ENSMUSG0000041147
Gene type	protein coding
RefSeq status	VALIDATED
Organism	Mus musculus
Lineage	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
	Muroidea; Muridae; Murinae; Mus; Mus
Also known as	Fancd1, RAB163
Expression	Broad expression in CNS E11.5 (RPKM 2.0), liver E14 (RPKM 1.6) and 24 other tissues See more
Orthologs	human all

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.


Transcript information (Ensembl)



The gene has 14 transcripts, all transcripts are shown below:

Name	Transcript ID	bp	Protein	Biotype	CCDS	UniProt	Flags
Brca2-201	ENSMUST00000044620.10	10724	<u>3329aa</u>	Protein coding	CCDS39411	P97929	TSL:5 GENCODE basic APPRIS P1
Brca2-210	ENSMUST00000202313.1	10517	<u>3329aa</u>	Protein coding	CCDS39411	<u>P97929</u>	TSL:1 GENCODE basic APPRIS P1
Brca2-208	ENSMUST00000202003.3	3473	<u>992aa</u>	Protein coding	84 2 6	A0A0J9YVI7	CDS 3' incomplete TSL:1
Brca2-206	ENSMUST00000201309.3	1340	No protein	Processed transcript	121	2	TSL:1
Brca2-203	ENSMUST00000201149.1	634 N	No protein	Processed transcript	(27)	5	TSL:5
Brca2-209	ENSMUST00000202192.1	588 1	No protein	Processed transcript	-	-	TSL:2
Brca2-214	ENSMUST00000202975.3	2534 1	No protein	Retained intron	8 2 0	2	TSL:2
Brca2-204	ENSMUST00000201165.1	1742	No protein	Retained intron	121	2	TSL:NA
Brca2-202	ENSMUST00000200686.3	937 1	No protein	Retained intron	(25)	5	TSL:2
Brca2-205	ENSMUST00000201226.1	864 1	No protein	Retained intron	-	-	TSL:2
Brca2-211	ENSMUST00000202693.1	688 1	No protein	Retained intron	8 2 0	2	TSL:3
Brca2-213	ENSMUST00000202837.1	669 1	No protein	Retained intron	121	-	TSL:3
Brca2-207	ENSMUST00000201678.1	646 N	No protein	Retained intron	1871	5	TSL:3
Brca2-212	ENSMUST00000202727.1	479 N	No protein	Retained intron	-	-	TSL:2
Brca2-205 Brca2-211 Brca2-213 Brca2-207 Brca2-212	ENSMUST00000201226.1 ENSMUST00000202693.1 ENSMUST00000202837.1 ENSMUST00000201678.1	864 M 688 M 669 M 646 M	No protein No protein No protein No protein	Retained intron Retained intron Retained intron Retained intron			TSL:2 TSL:3 TSL:3 TSL:3

The strategy is based on the design of Brca2-201 transcript, The transcription is shown below



江苏集萃药康生物科技股份有限公司


GemPharmatech Co., Ltd.

400-9660890

Forward strand

Genomic location distribution





Protein domain






江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

Mouse phenotype description(MGI)





Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).

According to the existing MGI data, Homozygous null mutants are embryonic lethal with abnormalities including growth retardation, neural tube defects, and mesoderm abnormalities; conditional mutations cause genetic instability and enhanced tumor formation; mutants with truncated BRCA2 protein survive, are small, infertile, show improper tissue differentiation and develop lymphomas and carcinomas.

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.



If you have any questions, you are welcome to inquire. Tel: 400-9660890



